In this webinar, you will learn:
- Antibody technologies for the design of unique antibody formats
- Advancements in engineering efforts for the development of functionally tailored antibodies, recombinant isotype antibody panels, and multivalent fragment antibody constructs
- Characterization of different bispecific antibody formats
- Next generation protein sequencing to aid in bispecific antibody design
- Optimize bispecific antibodies with kinetic analysis by surface plasmon resonance (SPR) and epitope mapping by hydrogen-deuterium exchange mass spectrometry (HDX-MS)
Abstract
Antibody engineers continue to push the boundaries of antibody technology, designing an ever-increasing number of unique antibody formats to generate next-generation therapeutics, improve diagnostic assays, and drive scientific research forward. This talk will present several recent advances in the application of antibody engineering across research and diagnostics, including species-matched and effector function-tailored antibodies for improved in vivo research, recombinant isotype panels for standardization of serological assays, multivalent fragment constructs for higher avidity diagnostic assays, and recent research comparing characteristics of different bispecific antibody formats.
Improving Antibody Function with Antibody Sequencing and Characterization
Characterizing engineered antibodies is crucial in their development for therapeutic and diagnostic purposes. The engineering process involves modifying antibody formats, which consequently changes antibody properties such as affinity, and stability. To address this, characterizing antibody properties such as protein sequence, epitopes, binding kinetics, and glycan profile becomes essential. Bispecific antibodies can be optimized with kinetic analysis by surface plasmon resonance (SPR) and epitope mapping by hydrogen-deuterium exchange mass spectrometry (HDX-MS). This information allows for rational engineering, ensuring the preservation and enhancement of desired properties in the engineered antibodies, ultimately optimizing their effectiveness and utility in various applications.
Speaker Bios
Iain Rogers, MBA
Rapid Novor
VP of Sales and Marketing
Iain began working in mass spectrometry and proteomics in 2004. Since then, he has founded and exited two startups and earned an MBA from Cornell University and Queen’s University. Iain joined Rapid Novor in 2021, to lead the commercialization of our technology.
Michael Fiebig, PhD
Absolute Biotech
Chief Scientific Officer
Dr. Michael Fiebig is the Chief Scientific Officer at Absolute Biotech. Michael studied Biochemistry before obtaining his doctoral degree from the University of Oxford. He joined Absolute Antibody in 2014 to develop the recombinant antibody catalog and many underlying technologies that now comprise a core part of the Absolute Biotech portfolio of products and services. He took over the role of Chief Scientific Officer in 2021.
Related Posts
Talk to Our Scientists.
We Have Sequenced 9000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.
Talk to Our Scientists.
We Have Sequenced 9000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics